Navigation Links
Epothilone in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

...upportive trial in patients with less advanced disease. Kosan's Hsp90 and epothilone Clinical Programs on Track for 2008 Kosan's TIME registration program is ...ancer who have not previously been treated with trastuzumab. Kosan's lead epothilone clinical candidate, KOS-1584, has demonstrated promising antitumor activity...

Study Findings Could Help In Developing A Better Drug Delivery System

...hat is in phase I studies. Endocyte has licensed its vitamin-targeting technology to Bristol-Myers Squibb to target Bristol-Myers Squibb's proprietary epothilone cancer chemotherapeutic agents. Source-Eurekalert VI ...
Epothilone in Medical Technology

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

HAYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated. The Phase 2 trial is an open-label, multi-center, monotherapy study ...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) presented updated data today from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on KOS-1803, a next-generation epothilone, showing a high level of antitumor activity and a favorable pharmacokinetic and safety profile in a broad range of in vitro tests and ...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors....

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

...atic breast cancer in combination with Herceptin(R) (trastuzumab). KOS-1584 epothilone product candidate is in a Phase 2 clinical trial in patients with non-small...s; Kosan' dependence on it license with Bristol-Myers Squibb to develop its epothilone products in order for Kosan to receive milestones or royalties, Kosan's dep...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

...Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the Am...S-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercial...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. For additional information on Kosan Biosciences, pleas...
Epothilone in Biological Technology

Kosan to Reacquire Epothilone Program From Roche

Kosan to Commence Phase 2 Clinical Program for KOS-1584 HAYWARD, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that Roche and Kosan are concluding their epothilone development and commercialization collaboration. The collabora...

FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer

PRINCETON, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of IXEMPRA(TM) (ixabepilone) as monotherapy for the treatment of patients with metastatic or locally advanced brea...

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

...arkets and her work with a broad range of compound classes and tumor types will be of significant value to Kosan as we advance our Hsp90 inhibitor and epothilone programs through later stages of development," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Recruiting an experienced and accomp...

Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs

...rams, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung cancer. The restructuring will primarily affect ...pany's reputation as a leader in polyketide technology as well as Hsp90 and epothilone drug discovery. We believe that this restructuring will strengthen our abil...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

...loma and in metastatic breast cancer, and its lead epothilone candidate, KOS-1584, in non-small cell lung cancer...herapy beginning in late 2008 and early 2009. -- epothilone KOS-1584 is a key asset in Kosan's pipeline. Kosan...hanisms. With the recent FDA approval of the first epothilone (BMS' ixabepilone), the epothilone class has gaine...

Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

...ter is primarily due to increased clinical costs in the Hsp90 inhibitor and epothilone programs, including costs associated with the initiation of the clinical tr...espimycin metastatic breast cancer clinical program, and the development of epothilone KOS-1584, which is entering Phase 2 in non-small cell lung cancer. We belie...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

...on and sustainability of multiple partnering arrangements and license agreements with third parties, including with respect to its Hsp90 inhibitor and epothilone programs; Kosan's need for additional financing; Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's depe...

Kosan Announces Third Quarter 2007 Financial Results

...gram in multiple myeloma and investment in Kosan's epothilone program, including KOS-1584 process development wh...nnounced that Roche and Kosan are concluding their epothilone development and commercialization collaboration. T...which Kosan will reacquire worldwide rights to its epothilone program and have full control of clinical developm...
Other Tags
(Date:7/31/2014)... WA (PRWEB) July 31, 2014 ... family practice provider? Community Health Center of Snohomish ... “ Pediatricians vs. Family Doctors ”. Many adults ... are available to them. Community Health Center hopes ... similarities and differences between the two. , ...
(Date:7/31/2014)... The shale gas development that has vaulted ... U.S. natural gas production has raised concerns that local ... similar to previous resource extraction experiences in Pennsylvania’s history. ... & Jefferson College’s (W&J) Center for Energy Policy & ... that the gas boom in Pennsylvania is still underway, ...
(Date:7/31/2014)... OR (PRWEB) July 31, 2014 Sales in ... from 2013 to 2014, according to radio talk show host ... been experiencing rapid growth since 1990. The US economy in ... Kleyne Hour Power of Water radio show, reported this information ... Live Foods, a worldwide manufacturer of organic and natural food ...
(Date:7/31/2014)... 2014 According to new research ... Mycoprotein), by Type (Tofu, Tofu-Based Product, Tempeh, TVP, ... Global Trends & Forecasts to 2019", defines and ... analysis and forecasting of the market value of ... report also identifies the driving and restraining factors ...
(Date:7/31/2014)... 31, 2014 Care Communications, Inc., (CARE) ... firm, has received the Elite Award for “Recruitment, Selection ... one of twelve elite awards presented as part of ... Work For” 2014 awards competition. This marks the ... Award in the competition. CARE has also been chosen ...
Breaking Medicine News(10 mins):Health News:Community Health Center of Snohomish County Reveals the Differences Between Pediatricians and Family Practice Providers 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 3Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2
(Date:7/30/2014)... 2014 ResearchMoz presents this ... Systems Market 2014-2024   Business Strategies, Industry Trends, and ... Market 2014-2024" offers the reader detailed analysis of ... ten years, alongside potential market opportunities to enter ... To view the table of contents for ...
(Date:7/30/2014)... they eat, the Food and Drug Administration (FDA) earlier ... label found on nearly every food product in the ... (C&EN), the weekly news magazine of the American ... fight that has ensued. , Britt Erickson, a senior ... Facts label has remained largely the same for two ...
(Date:7/30/2014)... a subject of major interest in neuroscience. A ... the distinct stages of Wallerian degeneration: transcription factor ... Although gene expression responses in the distal segment ... are known, differences in gene expression between the ... Yao and co-workers from Nantong University, China used ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
Other Contents